Trevi Therapeutics Inc (TRVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -42,759 | -47,911 | -29,065 | -29,152 | -33,940 |
| Depreciation Amortization | 144 | 147 | 303 | 563 | 649 |
| Accounts payable and accrued liabilities | -598 | 1,605 | -1,049 | 9 | 831 |
| Other Working Capital | -3,491 | 6,827 | -3,847 | -1,231 | 1,509 |
| Other Operating Activity | 4,615 | 1,076 | 1,948 | 1,636 | 2,005 |
| Operating Cash Flow | $-42,089 | $-38,256 | $-31,710 | $-28,175 | $-28,946 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -12 | -35 | -137 | -159 | N/A |
| Purchase Of Investment | -170,662 | -98,463 | -9,932 | -126,215 | N/A |
| Sale Of Investment | 76,567 | 76,970 | 69,497 | 19,001 | N/A |
| Investing Cash Flow | $-94,107 | $-21,528 | $59,428 | $-107,373 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -11 | -126 | -9,504 | -5,833 | N/A |
| Common Stock Issued | 121,108 | 47,464 | 142 | 117,387 | 13,720 |
| Other Financing Activity | -84 | 14,146 | 1,452 | -247 | 7,055 |
| Financing Cash Flow | $121,013 | $61,484 | $-7,910 | $111,307 | $20,775 |
| Beginning Cash Position | 34,097 | 32,397 | 12,589 | 36,830 | 45,001 |
| End Cash Position | 18,914 | 34,097 | 32,397 | 12,589 | 36,830 |
| Net Cash Flow | $-15,183 | $1,700 | $19,808 | $-24,241 | $-8,171 |
| Free Cash Flow | |||||
| Operating Cash Flow | -42,089 | -38,256 | -31,710 | -28,175 | -28,946 |
| Capital Expenditure | -12 | -35 | -137 | -159 | N/A |
| Free Cash Flow | -42,101 | -38,291 | -31,847 | -28,334 | -28,946 |